Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas

被引：0
|
作者：
Alexander M. Spence
Richard A. Peterson
Jeffrey D. Scharnhorst
Daniel L. Silbergeld
Robert C. Rostomily
机构：
[1] University of Washington,Department of Neurology, 356465
[2] University of Washington School of Medicine,Departments of Neurology and Neurological Surgery
来源：
Journal of Neuro-Oncology | 2004年 / 70卷
关键词：
anaplastic astrocytoma; glioblastoma multiforme; phase II; Tamoxifen; Temozolomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose and background: The aim of this study was to assess the frequency of response and toxicity in adults with recurrent anaplastic astrocytoma (AA) or glioblastoma multiforme (GM) treated with concurrent continuous TMZ and TMX.
引用
收藏
页码：91 / 95
页数：4
相关论文
共 50 条
  • [1] Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas
    Spence, AM
    Peterson, RA
    Scharnhorst, JD
    Silbergeld, DL
    Rostomily, RC
    JOURNAL OF NEURO-ONCOLOGY, 2004, 70 (01) : 91 - 95
  • [2] A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
    Khan, RB
    Raizer, JJ
    Malkin, MG
    Bazylewicz, KA
    Abrey, LE
    NEURO-ONCOLOGY, 2002, 4 (01) : 39 - 43
  • [3] A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
    Odia, Yazmin
    Kreisl, Teri N.
    Aregawi, Dawit
    Innis, Ellen K.
    Fine, Howard A.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 125 (01) : 191 - 195
  • [4] A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
    Yazmín Odia
    Teri N. Kreisl
    Dawit Aregawi
    Ellen K. Innis
    Howard A. Fine
    Journal of Neuro-Oncology, 2015, 125 : 191 - 195
  • [5] THE TEMOZOLOMIDE RESCUE STUDY: A PHASE II TRIAL OF CONTINUOUS (28/28) DOSE-INTENSE TEMOZOLOMIDE (TMZ) AFTER PROGRESSION ON CONVENTIONAL 5/28 DAY TMZ IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Perry, J.
    Mason, W.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J. F.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1063 - 1063
  • [6] The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
    Perry, J. R.
    Mason, W. P.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Peters, Katherine B.
    Lipp, Eric S.
    Miller, Elizabeth
    Herndon, James E., II
    McSherry, Frances
    Desjardins, Annick
    Reardon, David A.
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 349 - 356
  • [8] Retreatment with a prolonged temozolomide (TMZ) dosing schedule in patients (pts) with recurrent malignant gliomas (MG)
    Murray, C. E.
    D'Agostino, R., Jr.
    Lesser, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Katherine B. Peters
    Eric S. Lipp
    Elizabeth Miller
    James E. Herndon
    Frances McSherry
    Annick Desjardins
    David A. Reardon
    Henry S. Friedman
    Journal of Neuro-Oncology, 2018, 137 : 349 - 356
  • [10] Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas
    Blakeley, Jaishri O.
    Grossman, Stuart A.
    Mikkelsen, Tom
    Rosenfeld, Myrna R.
    Peereboom, David
    Nabors, L. Burt
    Chi, Andrew S.
    Emmons, Gary
    Ribas, Ignacio Garcia
    Supko, Jeffrey G.
    Desideri, Serena
    Ye, Xiaobu
    JOURNAL OF NEURO-ONCOLOGY, 2015, 125 (01) : 123 - 131
12345